Interaction Checker

Tretinoin interactions

Tretinoin (Retin-A, Renova, Altreno), a retinoid has 106 documented interactions across the FDA labels and fact sheets we index: 96 major, 9 moderate, 1 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Major interactions (96)

  • AcitretinretinoidMajor

    Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (Tretinoin label, Contraindications)

  • AdapaleneretinoidMajor

    Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (Tretinoin label, Contraindications)

  • Aminocaproic acidantifibrinolyticMajor

    Avoid concomitant use of tretinoin capsules and anti-fibrinolytic agents, such as tranexamic acid, aminocaproic acid or aprotinin [see Drug Interactions ( 7.4 )] . (Tretinoin label, Warnings and precautions)

  • AmiodaroneantiarrhythmicMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • AprepitantCYP3A4 inhibitorMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • ArmodafinilCNS stimulantMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • AtazanavirantiretroviralMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Azelastine and fluticasoneantihistamineMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • BeclomethasonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • BetamethasonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • BexaroteneretinoidMajor

    Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (Tretinoin label, Contraindications)

  • BosentanCYP3A4 inducerMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • BudesonidecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • Budesonide and formoterolcorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • CarbamazepineanticonvulsantMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • CenobamateanticonvulsantMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • CiclesonidecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • CimetidineH2 blockerMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Clarithromycinmacrolide antibioticMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • ClobazambenzodiazepineMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • ClobetasolcorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • CyclosporineimmunosuppressantMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • DarunavirantiretroviralMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Darunavir and cobicistatantiretroviralMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Deferasiroxiron supplementMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • DeflazacortcorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • DesonidecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • DexamethasonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • Diltiazemcalcium channel blockerMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • DronedaroneantiarrhythmicMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • EfavirenzantiretroviralMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Efavirenz, lamivudine, and tenofovirantiretroviralMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Elvitegravir, cobicistat, emtricitabine, and tenofovirantiretroviralMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Erythromycinmacrolide antibioticMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • EslicarbazepineanticonvulsantMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • EtravirineantiretroviralMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • EverolimusimmunosuppressantMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Fluconazoleazole antifungalMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • FludrocortisonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • FlunisolidecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • FluocinonidecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • FluticasonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • Fluticasone and salmeterolcorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • FosamprenavirantiretroviralMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • FosaprepitantCYP3A4 inhibitorMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • FosphenytoinanticonvulsantMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • GriseofulvinantifungalMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • HalobetasolcorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • HydrocortisonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • HydroxyureaantimetaboliteMajor

    • Leukocytosis: Consider administering cytoreductive chemotherapy (including an anthracycline if not contraindicated or hydroxyurea) with tretinoin capsules in the setting of leukocytosis, as clinically indicated. (Tretinoin label, Warnings and precautions)

  • ImatinibCYP3A4 inhibitorMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • IsoniazidantibioticMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • IsotretinoinretinoidMajor

    Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (Tretinoin label, Contraindications)

  • Itraconazoleazole antifungalMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • IvacaftorCYP3A4 inhibitorMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Ketoconazoleazole antifungalMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • LenacapavirantiretroviralMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Lopinavir and ritonavirantiretroviralMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • LorlatinibCYP3A4 inducerMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • MethylprednisolonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • MifepristoneCYP3A4 inhibitorMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Minocyclinetetracycline antibioticMajor

    Avoid concomitant use of isotretinoin and EMROSI because isotretinoin, a systemic retinoid, is also known to cause idiopathic intracranial hypertension. (Minocycline label, Warnings and precautions)

  • Mirabegronbeta-adrenergic agonistMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • MitapivatCYP3A4 inducerMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • MitotaneCYP3A4 inducerMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • ModafinilCNS stimulantMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • MometasonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • Nafcillinpenicillin antibioticMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • NefazodoneantidepressantMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • NevirapineantiretroviralMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • Nirmatrelvir and ritonavirantiviralMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Olopatadine and mometasoneantihistamineMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • OxcarbazepineanticonvulsantMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • PalbociclibCYP3A4 inhibitorMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • PerampanelanticonvulsantMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • PhenobarbitalbarbiturateMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • Phentermine and topiramateCNS stimulantMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • PhenytoinanticonvulsantMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • Posaconazoleazole antifungalMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • PrednisolonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • PrednisonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • PrimidoneanticonvulsantMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • RanolazineQT-prolonging drugMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • RifabutinantibioticMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • RifampinantibioticMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • RifapentineantibioticMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • RitonavirantiretroviralMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Suvorexantsedative-hypnoticMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • SuzetrigineCYP3A4 inducerMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • Tetracyclinetetracycline antibioticMajor

    Concomitant use of isotretinoin and tetracycline should be avoided because isotretinoin, a systemic retinoid, is also known to cause pseudotumor cerebri. (Tetracycline label, Warnings)

  • Ticagrelorantiplatelet agentMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • TopiramateanticonvulsantMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • Tranexamic acidantifibrinolyticMajor

    Avoid concomitant use of tretinoin capsules and anti-fibrinolytic agents, such as tranexamic acid, aminocaproic acid or aprotinin [see Drug Interactions ( 7.4 )] . (Tretinoin label, Warnings and precautions)

  • TriamcinolonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • Verapamilcalcium channel blockerMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Voriconazoleazole antifungalMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

Moderate interactions (9)

  • Arsenic trioxideQT-prolonging drugModerate

    Hepatotoxicity: Elevated aspartate aminotransferase (AST), alkaline phosphatase and serum bilirubin have occurred in patients with newly-diagnosed low-risk APL treated with arsenic trioxide in combination with tretinoin. (Arsenic trioxide label, Warnings and precautions)

  • Bismuth subcitrate, metronidazole, and tetracyclineantibioticModerate

    The concomitant use of other products (e.g., tetracyclines) that can cause intracranial hypertension may increase the risk. (Tretinoin label, Warnings and precautions)

  • Calcium chlorideModerate

    Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (Calcium chloride label, Drug interactions)

  • Demeclocyclinetetracycline antibioticModerate

    The concomitant use of other products (e.g., tetracyclines) that can cause intracranial hypertension may increase the risk. (Tretinoin label, Warnings and precautions)

  • Doxycyclinetetracycline antibioticModerate

    The concomitant use of other products (e.g., tetracyclines) that can cause intracranial hypertension may increase the risk. (Tretinoin label, Warnings and precautions)

  • Elexacaftor, tezacaftor, and ivacaftorModerate

    Patients with elevated vitamin A levels may be at increased risk. (Elexacaftor, tezacaftor, and ivacaftor label, Warnings and precautions)

  • MethotrexateimmunosuppressantModerate

    Monitor patients receiving XATMEP with other potential hepatotoxins (e.g., azathioprine, retinoids, and sulfasalazine) for possible signs of hepatotoxicity. (Methotrexate label, Drug interactions)

  • OrlistatModerate

    The effect of ORLISTAT on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time [see Clinical Pharmacology (12.3) , and Warnings and Precautions (5.1) ] . (Orlistat label, Drug interactions)

  • Tigecyclinetetracycline antibioticModerate

    The concomitant use of other products (e.g., tetracyclines) that can cause intracranial hypertension may increase the risk. (Tretinoin label, Warnings and precautions)

Minor mentions (1)

  • Calcium gluconateMinor

    Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (Calcium gluconate label, Drug interactions)

Check Tretinoin against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.